Phase 2; High Dose MYOBLOC (20,000 Units)

DRUG2 trials

Sponsors

Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC

Conditions

Cerebral PalsyCerebrovascular AccidentCervical Spinal Cord InjuryMultiple SclerosisSpasticityTraumatic Brain Injury

Phase 2

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

TerminatedNCT04099667

Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLCSpasticity

Start: 2019-12-17End: 2023-03-24Updated: 2026-05-22

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

TerminatedNCT04815967

Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLCCerebral Palsy, Cerebrovascular Accident, Cervical Spinal Cord Injury +3

Start: 2021-11-02End: 2023-04-23Updated: 2026-05-27